Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $53
Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com
Top 3 Health Care Stocks That May Rocket Higher In April
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Express News | Bristol-Myers Squibb : HSBC Cuts Target Price to $47 From $56
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Is Bristol-Myers Squibb Company (NYSE:BMY) A High Quality Stock To Own?
Bristol-Myers Squibb First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $56 From $55, Maintains Neutral Rating
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $53 From $62, Maintains Equalweight Rating
Express News | Exclusive-Pharma Tariffs Would Increase U.S. Production Costs, Reduce Competitiveness of U.S. Drug Exports: Report
Express News | Exclusive-Pharma Tariffs Would Raise U.S. Prices by as Much as 12.9% if Fully Passed on: Report
Express News | Exclusive-25% Pharma Tariffs Would Increase U.S. Drug Costs by $51 Bln Annually: Report Commissioned by Industry's U.S. Trade Group
Bristol-Myers Squibb (BMY) Receives a Hold From Argus Research
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Ironwood Pharma (IRWD) and Repligen (RGEN)
Bristol-Myers Squibb Company (BMY): A Growing Dividend Stock With Low PE Ratio
Express News | Bristol-Myers Squibb Co : BofA Global Research Raises Price Objective to $56 From $54
Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $62
S&P 500 Rallies 2% On Nvidia, Tesla Gains — But Market Mood Stuck In 'Fear'